MA48800A - Cycles 5-5 fusionnés utilisés en tant qu'inhibiteurs de c5a - Google Patents

Cycles 5-5 fusionnés utilisés en tant qu'inhibiteurs de c5a

Info

Publication number
MA48800A
MA48800A MA048800A MA48800A MA48800A MA 48800 A MA48800 A MA 48800A MA 048800 A MA048800 A MA 048800A MA 48800 A MA48800 A MA 48800A MA 48800 A MA48800 A MA 48800A
Authority
MA
Morocco
Prior art keywords
inhibitors
fused cycles
fused
cycles
Prior art date
Application number
MA048800A
Other languages
English (en)
Inventor
Pingchen Fan
Christopher W Lange
Rebecca M Lui
Viengkham Malathong
Venkat Reddy Mali
Sreenivas Punna
Yibin Zeng
Penglie Zhang
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of MA48800A publication Critical patent/MA48800A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Liquid Crystal Substances (AREA)
  • Glass Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Insulating Materials (AREA)
MA048800A 2017-05-31 2018-05-29 Cycles 5-5 fusionnés utilisés en tant qu'inhibiteurs de c5a MA48800A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762513025P 2017-05-31 2017-05-31

Publications (1)

Publication Number Publication Date
MA48800A true MA48800A (fr) 2020-04-08

Family

ID=64455572

Family Applications (1)

Application Number Title Priority Date Filing Date
MA048800A MA48800A (fr) 2017-05-31 2018-05-29 Cycles 5-5 fusionnés utilisés en tant qu'inhibiteurs de c5a

Country Status (15)

Country Link
US (2) US10683294B2 (fr)
EP (1) EP3630774B1 (fr)
JP (1) JP7141129B2 (fr)
KR (1) KR102586710B1 (fr)
CN (1) CN111032658B (fr)
AR (1) AR111841A1 (fr)
AU (1) AU2018277523B2 (fr)
CA (1) CA3064025A1 (fr)
ES (1) ES2934507T3 (fr)
IL (1) IL270842B2 (fr)
MA (1) MA48800A (fr)
MX (1) MX391392B (fr)
TW (1) TWI813570B (fr)
WO (1) WO2018222601A1 (fr)
ZA (1) ZA201907755B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7141130B2 (ja) * 2017-05-31 2022-09-22 ケモセントリックス，インコーポレイティド Ｃ５ａ阻害剤としての６－５融合環
ES2934507T3 (es) 2017-05-31 2023-02-22 Chemocentryx Inc Anillos fusionados en 5-5 como inhibidores de C5a
MX2020006460A (es) * 2017-12-22 2020-11-06 Chemocentryx Inc Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar.
US10828285B2 (en) 2017-12-22 2020-11-10 Chemocentryx, Inc. Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors
SG11202009588PA (en) * 2018-04-02 2020-10-29 Chemocentryx Inc PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS
WO2021007386A1 (fr) 2019-07-10 2021-01-14 Chemocentryx, Inc. Indanes en tant qu'inhibiteurs de pd-l1
CN112300169B (zh) * 2019-07-26 2022-03-04 上海美迪西生物医药股份有限公司 吡咯并吡唑类衍生物、其制备方法及其在医药上的应用
AU2020368393B2 (en) 2019-10-16 2026-01-08 Chemocentryx, Inc. Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases
BR112022006279A2 (pt) 2019-10-16 2022-06-28 Chemocentryx Inc Heteroaril-bifenil aminas para o tratamento de doenças pd-l1
CN116249692B (zh) * 2020-09-28 2024-08-23 四川科伦博泰生物医药股份有限公司 吡唑类化合物及其制备方法和用途
WO2022093971A1 (fr) 2020-10-28 2022-05-05 Chemocentryx, Inc. Méthodes de traitement de l'hidradénite suppurée

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100904157B1 (ko) 2000-08-10 2009-06-23 파마시아 이탈리아 에스.피.에이. 키나제 억제제로서 활성인 비사이클로-피라졸, 이의제조방법 및 이를 포함하는 약제학적 조성물
ATE404553T1 (de) 2000-09-29 2008-08-15 Neurogen Corp Hochaffine kleinmolekülige c5a-rezeptor- modulatoren
SE524438C2 (sv) 2000-10-05 2004-08-10 Magnus Georg Goertz Fjärrstyrt dörrelaterat låsarrangemang, första och andra datorpogramprodukt, bärande medium och ett datorlösbart medium
US7902179B2 (en) 2001-04-26 2011-03-08 Ajinomoto Co., Inc. Heterocyclic compounds
ITMI20012025A1 (it) 2001-09-28 2003-03-28 Dompe Spa Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono
AU2003225971A1 (en) 2002-03-28 2003-10-13 Yang Gao Substituted biaryl amides as c5a receptor modulators
EP1487798A4 (fr) 2002-03-28 2005-07-13 Neurogen Corp Tetrahydroisoquinoleines substituees servant de modulateurs du recepteur c5a
WO2003084524A1 (fr) 2002-03-29 2003-10-16 Neurogen Corporation Therapie combinatoire pour le traitement de maladies faisant intervenir des composants inflammatoires
AU2003265395A1 (en) 2002-08-14 2004-03-03 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
AU2003265625A1 (en) 2002-08-21 2004-03-11 Neurogen Corporation Amino methyl imidazoles as c5a receptor modulators
US7342115B2 (en) 2002-11-08 2008-03-11 Neurogen Corporation 3-substituted-6-aryl pyridines
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US20040214856A1 (en) 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
AU2003902354A0 (en) 2003-05-15 2003-05-29 Harkin, Denis W. Treatment of haemorrhagic shock
WO2005007087A2 (fr) 2003-07-03 2005-01-27 Neurogen Corporation Derives (heterocycloalkyl)methyle substitues de type azole utilises comme modulateurs des recepteurs c5a
US7906528B2 (en) * 2004-10-05 2011-03-15 Novartis International Pharmaceutical Ltd. Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
US20070112015A1 (en) 2005-10-28 2007-05-17 Chemocentryx, Inc. Substituted dihydropyridines and methods of use
AU2009259867A1 (en) 2008-06-20 2009-12-23 Genentech, Inc. Triazolopyridine JAK inhibitor compounds and methods
CN102264227B (zh) 2008-12-22 2014-07-23 凯莫森特里克斯股份有限公司 C5aR拮抗剂
US20110275639A1 (en) 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
RS56332B1 (sr) 2010-06-24 2017-12-29 Chemocentryx Inc Antagonisti c5ar
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
KR20150042271A (ko) 2012-08-16 2015-04-20 얀센 파마슈티카 엔.브이. N형 칼슘 채널 차단제로서의 치환된 피롤로피라졸
CN103421006B (zh) 2013-08-18 2016-06-22 上海师范大学 2,3,5,7-四取代二氢吡唑并六氢吡啶衍生物及其制备方法和应用
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
AU2017246228B2 (en) 2016-04-04 2021-04-15 Chemocentryx, Inc. Soluble C5aR antagonists
JP7141130B2 (ja) 2017-05-31 2022-09-22 ケモセントリックス，インコーポレイティド Ｃ５ａ阻害剤としての６－５融合環
ES2934507T3 (es) 2017-05-31 2023-02-22 Chemocentryx Inc Anillos fusionados en 5-5 como inhibidores de C5a
MX2020006460A (es) 2017-12-22 2020-11-06 Chemocentryx Inc Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar.
US10828285B2 (en) 2017-12-22 2020-11-10 Chemocentryx, Inc. Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors
SG11202009588PA (en) 2018-04-02 2020-10-29 Chemocentryx Inc PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS

Also Published As

Publication number Publication date
JP2020522483A (ja) 2020-07-30
IL270842B2 (en) 2023-05-01
KR20200013720A (ko) 2020-02-07
TWI813570B (zh) 2023-09-01
AU2018277523B2 (en) 2022-06-23
IL270842B1 (en) 2023-01-01
US11479553B2 (en) 2022-10-25
EP3630774B1 (fr) 2022-11-23
CN111032658A (zh) 2020-04-17
CA3064025A1 (fr) 2018-12-06
CN111032658B (zh) 2022-12-20
MX2019014292A (es) 2022-04-07
KR102586710B1 (ko) 2023-10-10
TW201902897A (zh) 2019-01-16
ES2934507T3 (es) 2023-02-22
MX391392B (es) 2025-03-21
JP7141129B2 (ja) 2022-09-22
AR111841A1 (es) 2019-08-21
WO2018222601A1 (fr) 2018-12-06
EP3630774A1 (fr) 2020-04-08
US20210009594A1 (en) 2021-01-14
RU2019142985A3 (fr) 2021-09-03
US10683294B2 (en) 2020-06-16
EP3630774A4 (fr) 2020-10-07
BR112019025230A2 (pt) 2020-06-16
IL270842A (en) 2020-01-30
AU2018277523A1 (en) 2019-12-05
ZA201907755B (en) 2023-05-31
RU2019142985A (ru) 2021-06-30
US20180346471A1 (en) 2018-12-06

Similar Documents

Publication Publication Date Title
MA48800A (fr) Cycles 5-5 fusionnés utilisés en tant qu'inhibiteurs de c5a
MA48803A (fr) Cycles 6-5 fusionnés utilisés en tant qu'inhibiteurs de c5a
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA49566A (fr) Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiques
MA54076A (fr) 2-amino-n-hétéroaryl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
EP3873468A4 (fr) 2-amino-n-phényl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
MA41551A (fr) Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA51438A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
MA47013A (fr) Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase
MA48994A (fr) Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
MA42659A (fr) Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp
MA51878A (fr) Composés d'aminothiazole en tant qu'inhibiteurs de c-kit
MA47099A (fr) Composés hétéroaromatiques bicycliques utilisés en tant qu'immunomodulateurs
MA47460A (fr) Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
MA47120A (fr) Dérivés pyridine utilisés en tant qu'immunomodulateurs
EP3386981A4 (fr) Hétérocycles utiles en tant qu'agents anticancereux
MA46228A (fr) Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll
MA40587A (fr) Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak
MA45244A (fr) Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
MA42990A (fr) Composés utiles en tant qu'immunomodulateurs
MA42919A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
MA49374A (fr) Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine
MA42918A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
MA51429A (fr) Dérivés amino-fluoropipéridines utilisés en tant qu'inhibiteur de kinase